Loading...
01/10 16:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Financial performance shows improvement with increased gross margins and reduced losses, but challenges remain with sales leadership changes and guidance reduction. The Q&A reveals uncertainties in deal timing and sales leadership, though no order cancellations occurred. Raised revenue guidance for 2025 is positive, yet the lack of 2026 guidance and management's vague responses add uncertainty. Overall, the sentiment is neutral due to balancing positive financial trends with leadership and guidance concerns.
Revenue $29.4 million, representing 3% growth over the third quarter of last year. The growth was attributed to strong treatment utilization and disciplined pricing across consoles and consumables.
Product Revenue $20.6 million, slightly ahead of $20.3 million in the prior year period. This included console sales of $8.3 million and consumable sales of $12.2 million.
Service and Other Revenue $8.9 million, a 6% increase from $8.4 million in the prior year period. Recurring revenue from the sale of Tablo consumables and service was $21.1 million, slightly ahead of the third quarter of 2024.
Non-GAAP Gross Margin 39.9%, a 350 basis point increase from last year. Excluding a 130 basis point headwind from manufacturing overhead, it would have been above 41%. Product gross margin increased to 45.7% from 43.2% in the prior year, and service and other gross margin more than doubled to 24.8% from 12.5%.
Non-GAAP Operating Expenses $22.1 million, a 17% decline compared to $26.5 million in the third quarter of 2024. This reflects the impact of actions taken to remove $80 million of annualized spend.
Non-GAAP Operating Loss $10.4 million, over 35% lower than the $16.1 million in the prior year period.
Non-GAAP Net Loss $12.4 million, 39% lower than $20.2 million in the third quarter of 2024.
Cash Usage Approximately $6 million during the quarter, driven by expanding gross margin, lower operating expenses, and inventory optimization.
Tablo console sales: Increased by 8% in Q3 2025, with growing acute customer demand for in-sourcing dialysis using Tablo technology.
Clinical effectiveness: Presented data from over 1 million Tablo treatments across 750 facilities, showing rigorous treatment goals and benefits for critically ill patients.
Market opportunity: Outset Medical is expanding in large acute care markets, with nearly 1,000 acute sites using Tablo and a run rate of 1 million treatments per year.
Customer base expansion: Hundreds of customer master sales and service agreements are in place, with significant growth potential within the current customer base and new customer conversions.
Gross margin: Non-GAAP gross margin reached 39.9% in Q3 2025, with a path to 50% milestone. Product gross margin increased to 45.7%.
Expense management: Non-GAAP operating expenses declined by 17% to $22.1 million in Q3 2025, reflecting disciplined spending and a drive to profitability.
Sales leadership change: Head of Sales resigned, and sales leadership team now reports directly to the CEO. Search for a new Head of Sales is underway.
Revenue guidance revision: 2025 revenue guidance revised to $115-$120 million, down from $122-$126 million, due to timing shifts in large sales opportunities.
Sales Process Challenges: Several large opportunities in the final stages of the sales process were delayed, shifting expected revenue from Q3 and Q4 2025 into 2026. This indicates challenges in closing deals within anticipated timelines, particularly with large health systems requiring multiple approvals.
Leadership Disruption: The resignation of the Head of Sales and the ongoing search for a replacement may cause internal disruption in Q4 2025, potentially impacting sales performance and operational stability.
Revenue Guidance Revision: 2025 revenue guidance was revised downward from $122-$126 million to $115-$120 million, reflecting slower-than-expected deal closures and other operational challenges.
Customer Ordering Patterns: Discrepancies between customer ordering patterns and actual utilization of Tablo systems have impacted recurring revenue visibility and forecasting accuracy. This issue is expected to persist into 2026.
Manufacturing Under-Absorption: A 130 basis point headwind from under-absorption of manufacturing overhead affected gross margins in Q3 2025. This issue is expected to have a diminishing but ongoing impact into 2026.
Market Execution Risks: Despite growing demand, the company faces challenges in aligning its operational execution with market opportunities, as evidenced by slower-than-expected revenue growth and deal closures.
Revenue Guidance: Revised 2025 revenue guidance to a range of $115 million to $120 million, down from the prior guidance of $122 million to $126 million.
Gross Margin: Expect gross margin for the full year 2025 to be in the high 30% range, with a path to reach 50% in the future.
Operating Expenses: Operating expenses for 2025 are expected to remain in the low $90 million range.
Cash Flow: Anticipate using less than $50 million in cash for 2025, a significant reduction from over $100 million used in 2024. Cash balances are expected to be sufficient through cash flow breakeven and beyond.
Sales Opportunities: Several large sales opportunities are expected to close over the fourth quarter of 2025 and into 2026, with a focus on enterprise-wide in-sourcing deals involving large health systems.
Market Demand: Hospital demand for in-sourcing dialysis with Tablo is growing, supported by clinical, operational, and financial benefits. This trend is expected to support growth for many years.
Customer Pipeline: The sales pipeline has grown significantly compared to last year, with the average size of sales opportunities increasing by more than 20%.
Treatment Revenue: Treatment revenue is expected to normalize in 2026 as ordering patterns from large acute care customers align more closely with actual utilization.
Manufacturing Efficiency: Progress is being made to optimize inventory levels and increase production, which will mitigate gross margin impacts from manufacturing under-absorption in 2026.
Market Opportunity: The company sees significant growth potential in the acute care market, with plans to expand within the current customer base and convert new customers.
The selected topic was not discussed during the call.
The earnings call presents a mixed picture. Financial performance shows improvement with increased gross margins and reduced losses, but challenges remain with sales leadership changes and guidance reduction. The Q&A reveals uncertainties in deal timing and sales leadership, though no order cancellations occurred. Raised revenue guidance for 2025 is positive, yet the lack of 2026 guidance and management's vague responses add uncertainty. Overall, the sentiment is neutral due to balancing positive financial trends with leadership and guidance concerns.
The earnings call shows strong financial performance with reduced losses and improved cash position. Conservative guidance is balanced by optimism in recurring revenue and pipeline strength. The Q&A section highlights strategic improvements in sales productivity and market expansion, particularly in enterprise and home hemodialysis channels. Concerns about cash burn in 2026 are noted but don't overshadow the overall positive outlook. Given the strategic initiatives and strong recurring revenue, the stock is likely to experience a positive movement in the short term.
The earnings call presents a positive outlook with revenue and recurring revenue growth, improved gross margins, and reduced operating expenses. The Q&A section reinforced confidence in sales transformation and balance sheet improvements. Despite conservative guidance, the company is on track for a strong 2025 with reduced cash usage and a focus on market expansion. The shareholder return plan is also a positive aspect. However, regulatory and supply chain risks are noted, but the overall sentiment is positive, predicting a 2% to 8% stock price increase.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
